

1 **Title:** An Open-label Clinical Study of Brief Submaximal Cardiopulmonary Testing in Pre-
2 surgical Evaluation: Feasibility of implementation.

3
4
5 Zyad J. Carr (M.D.)^{a, b}, Daniel Agarkov (M.D.)^{a, b}, Judy Li (B.S.)^a, Jean Charchafliet (M.D.)^{a, b},
6 Andres Brenes-Bastos (M.D.)^{a, b}, Jonah Freund, (B.Sc., Candidate)^{a, b}, Jill Zafar (M.D.)^{a, c}, Robert
7 B. Schonberger (M.D, M.H.C.D.S.)^{a, b}, Paul Heerdt (M.D., Ph.D.)^{a, b}

8
9

10 ^aYale University School of Medicine, New Haven, Connecticut USA

11
12 ^bDepartment of Anesthesiology, Yale New Haven Hospital, New Haven, Connecticut USA

13
14 ^cDepartment of Anesthesiology, Bridgeport Hospital, Bridgeport, Connecticut USA

15
16 **Corresponding author:** Zyad J. Carr, M.D. 333 Cedar St., TMP-3, New Haven, Connecticut
17 06510. (203)-785-3689. zyad.carr@yale.edu

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Abstract**

48 **Objectives:** We tested the logistic feasibility of integrating brief submaximal cardiopulmonary
49 exercise testing (smCPET) in a pre-surgical evaluation (PSE) clinic.

50 **Design:** Prospective open-label clinical device trial.

51 **Setting:** Pre-surgical evaluation clinic.

52 **Participants:** 43 participants who met criteria of i) age ≥ 60 years old, ii) revised cardiac risk
53 index of ≤ 2 , iii) self-reported metabolic equivalents (METs) of ≥ 4.6 (i.e. ability to climb 2 flights
54 of stairs), and iv) presenting for noncardiac surgery.

55 **Interventions:** Pre-intervention self-reported METs, Duke Activity Status Index (DASI)
56 surveys, smCPET trial, Borg survey of perceived exertion, and post-intervention survey.

57 **Measurements:** Feasibility endpoints were 1) operational efficiency as measured by length of
58 time of experimental session ≤ 20 minutes, 2) no more than moderate perceived physical
59 exertion as quantified by a modified Borg survey of perceived exertion of ≤ 7 in the absence of
60 observed complications, 3) high participant satisfaction with smCPET task execution,
61 represented as a score of ≥ 8 , and 4) high patient satisfaction with scheduling of smCPET testing,
62 represented as a score of ≥ 8 .

63 **Results:** Session time was 16.9 minutes (± 6.8). Post-test modified Borg survey was 5.35 (± 1.8),
64 corresponding to moderate perceived exertion. Satisfaction [on a scale of 1 (worst) to 10 (best)]
65 regarding ease of smCPET tasks was 9.6 (± 0.7) and mean patient satisfaction with smCPET
66 scheduling was 9.5 (± 1.5). Operational efficiency was achieved after 10-15 experimental
67 sessions.

68 **Conclusions:** Our findings suggest that smCPET integration in a PSE clinic; 1) is time efficient
69 2) shows high participant satisfaction with task, and 3) rapidly achieved operational efficiency.

70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92

Trial Registration: ClinicalTrials.gov Registration: #NCT05743673. Principal Investigator: Zyad J. Carr, M.D. Date of Registration: 5-12-2023.

Strengths and limitations of this study

- We examined patient- and logistic-centered acceptance of study procedures within the environment of a high-volume preoperative surgical evaluation clinic.
- Study procedures were well tolerated, and participants readily accepted submaximal cardiopulmonary exercise testing with high satisfaction with device use, scheduling, and perceived exertion.
- User operational efficiency developed over 10-15 sessions of use.
- This feasibility study met our proposed endpoints but is comprised of a small sample of participants, limiting its generalizability to larger populations.

Keywords: Preoperative evaluation, submaximal cardiopulmonary exercise test, cardiac, pulmonary, evaluation, risk stratification

93 **Background**

94 Functional capacity or exercise tolerance, as measured by self-reported metabolic equivalents
95 (METs), remains a cornerstone of preliminary assessment of fitness for surgery. METs are
96 defined as multiples of the basal metabolic rate, conventionally defined as $3.5 \text{ ml.kg}^{-1}.\text{min}^{-1}$.
97 Self-reported ability to climb one flight of stairs has a general consensus of 4 METs¹. A
98 threshold of <4.6 METs (self-reported inability to climb two flights of stairs) has been observed
99 to correlate with major adverse cardiac events, all-cause mortality, and higher rates of
100 perioperative complications²⁻⁴. However, self-reported and physician estimated METs remain
101 insensitive in the accurate estimation of peak METs^{5 6}. Similarly, preoperative risk prediction
102 tools are fragmented or have demonstrated significant limitations in capturing at-risk populations
103 prior to surgical evaluation⁷. Thus, simple, reliable, and sensitive methods to improve the
104 precision of preoperative evaluation continues to be an area of importance in preoperative
105 assessment and the individualized identification of high-risk patients.

106 Traditional cardiopulmonary exercise testing (CPET) provides objective assessments of
107 cardiopulmonary performance by analyzing measures of cellular respiration at rest and during
108 exercise. Typically performed by measuring resting gas exchange followed by commencement of
109 maximal exercise to expose pathophysiological impairments. CPET usually exploits a symptom-
110 limited approach to stationary-cycle ergometer-derived exercise with a 3-minute resting stage, 3
111 minutes of unloaded cycling, and a 10-12 minute ramp stage with increasing resistance until
112 terminated by the participant⁸. Abnormalities have been shown to be associated with
113 perioperative morbidity after noncardiac surgery⁹. A peak VO_2 of $<15 \text{ ml/kg/min}$ has been
114 frequently reported in the literature as a threshold for elevated perioperative cardiopulmonary
115 complications in patients after thoracic and major noncardiac surgery¹⁰⁻¹³. In addition, CPET-

116 derived peak VO_2 has been observed to predict surgical site infection, postoperative respiratory
117 failure, and increased risk of critical care readmission but not 30-day mortality and non-fatal
118 myocardial infarction¹⁴. Despite its prognostic value for perioperative complications, traditional
119 CPET has been limited in its widespread adoption for preoperative evaluation due to limited
120 availability, required technical skills, necessity of maximal patient effort, complexity of task, and
121 cost.

122 In contrast to traditional CPET, submaximal cardiopulmonary exercise test (smCPET) utilizes
123 graded exercise and concomitant gas exchange analysis to provide a granular and personalized
124 assessment of cardiopulmonary performance⁸. Several advantages are provided by smCPET over
125 traditional CPET. First, a submaximal exercise effort is required since it analyzes the oxygen
126 uptake efficiency slope (OUES) to extrapolate reliable estimates of peak METs and peak VO_2 ¹⁵⁻
127 ¹⁷. The OUES predictive capability allows effort-independent estimation of extrapolated peak
128 cardiopulmonary functional reserve, a particular advantage in deconditioned, frail, or
129 functionally limited patient populations. Furthermore, as a time-limited assessment, smCPET
130 may be efficiently integrated into conventional clinic schedules. Lastly, new devices have
131 continued to miniaturize the smCPET footprint, permitting easy storage and transport. smCPET
132 has demonstrated reliable prediction of length of stay and prediction of postoperative
133 complications after noncardiac surgery¹⁸.

134 Despite these advantages, widespread adoption of smCPET for the purposes of preoperative
135 evaluation has not been observed. Thus, it is unclear if smCPET can be feasibly integrated into a
136 high-volume pre-surgical evaluation clinic setting.

137 **Study Objectives:** We examined the feasibility of integration of brief smCPET into a high-
138 volume pre-surgical evaluation (PSE) clinic of a large quaternary care facility. This initial study

139 stage was performed for the purpose of determining the adequacy of study and patient-centered
140 processes of the primary observational study which will examine the relationship of smCPET
141 and perioperative outcomes, as measured by the postoperative morbidity survey (POMS)¹⁹. Our
142 measured feasibility endpoints were 1) operational efficiency as measured by length of time of
143 experimental session ≤ 20 minutes, 2) no more than moderate perceived physical exertion as
144 quantified by a modified Borg survey of perceived exertion of ≤ 7 in the absence of observed
145 complications, 3) high participant satisfaction with smCPET task execution, represented as a
146 score of ≥ 8 , and 4) high patient satisfaction with scheduling of smCPET testing, represented as a
147 score of ≥ 8 .

148 A prior study examining CPET and subjective clinician estimation had a sensitivity of 19.2% in
149 the identification of patients with low functional capacity (≤ 4 METs)¹⁴. We were interested in
150 quantifying if this was also present in our feasibility cohort using smCPET equivalents.

151 Secondary outcomes included a comparison of differences between 1) self-reported METs
152 survey vs. smCPET equivalent (extrapolated peak METs), 2) Duke Activity Status Index²⁰
153 (DASI) vs. smCPET equivalent (extrapolated peak METs) and 3) estimated DASI maximal
154 oxygen consumption (estimated peak VO_2) vs. smCPET equivalent (extrapolated peak VO_2).

155 **Materials and Methods**

156 **Study Design:** This is an ongoing prospective open-label clinical device trial approved by the
157 Yale University Institutional Review Board (IRB#2000033885; ClinicalTrials.gov Registry.
158 #NCT05743673. Principal Investigator: Zyad J. Carr, M.D. Date of Registration: 5-12-2023).

159 **Study Population:** We successfully enrolled 43 participants who met the inclusion criteria of
160 age ≥ 60 years old, with a revised cardiac risk index²¹ of ≤ 2 , and self-endorsed subjective
161 metabolic equivalents of ≥ 4 , presenting for moderate to high-risk noncardiac surgery. The aim

162 was to recruit 40 participants for this initial feasibility stage of the study. We estimated this
163 number to be adequate to identify any study-related logistic process problems, patient-centered
164 outcome deficiencies, and to determine operational efficiency.

165 We pre-screened by chart review and excluded potential participants with recorded severe or
166 critical heart valve disease, active exertional angina, non-ambulation, gait abnormalities, end-
167 stage renal disease, severe peripheral vascular disease, and neurological motor deficits. We
168 excluded non-English speaking participants, those under legal guardianship, and participants
169 documented to not have personal health care decision-making capacity. After pre-screening, a
170 phone call was placed by a study team member to the potential participant, and eligible
171 participants were invited for in-person informed consent, preoperative evaluation, questionnaire
172 assessment of METs, and a smCPET experimental session.

173 **Testing Environment:** Testing was performed at the PSE Clinic at Yale New Haven Hospital
174 which is typically responsible for approximately >40,000 preoperative evaluations per year. On a
175 daily basis, the PSE clinic is staffed by an anesthesiologist, 2 resident physicians, 3 certified
176 nurse practitioners and 6 nursing staff and contains six exam rooms.

177 **Study Apparatus:** The FDA-approved Shape II® system is a compact cardiopulmonary breath
178 by breath exercise testing system that uses sub-maximal exercise effort to generate multiple
179 quantitative measures of actual and extrapolated peak exercise tolerance. The device has been
180 previously validated to conventional CPET measurements²². The compact design allows all the
181 necessary equipment to be placed on a standard rolling cart and it was deployed in a PSE clinic
182 examination room (2.4 x 2.4 meters). The device requires 2 minutes of baseline data, 3 minutes
183 of escalating exercise using a stationary step and 1 minute of recovery data to generate a variety
184 of individual measures of cardiac and pulmonary physiological data (**Supplementary Table 1**).

185 **Study procedures:** On presentation to the PSE clinic, participants received height/weight and
186 vital sign measurements (heart rate, blood pressure and pulse oximetry). Informed consent was
187 performed, and participants were instructed on smCPET testing (~5 minutes). Session time was
188 measured from the beginning of pre-test METs questionnaires until the termination of the
189 smCPET recovery phase. Study pre-test instruments included a self-reported 7-question METs
190 assessment and the 12-question DASI survey. A post-test modified Borg survey of perceived
191 exertion was performed after smCPET session and was recorded immediately after termination
192 of the smCPET trial. After study interventions, a standard preoperative evaluation was
193 completed, and the participant was discharged. A 24-hour post-experiment survey of
194 minor/major complication and patient satisfaction was performed by telephone (**Supplementary**
195 **Table 2**). With the exception of the patient satisfaction survey, all survey instruments were
196 adapted from prior publications²³⁻²⁵. DASI peak METs and peak VO₂ was calculated from
197 individual participants DASI score using the recommended formula.

198 **Data analysis:** Continuous variables are described as mean (standard deviation), ordinal
199 variables as median (range), and categorical variables as number (percent).

200 **Results**


201 **Participant recruitment:** Participants were recruited from June 2023 through October 2023. We
202 identified 209 potential participants that met eligibility criteria, 6 did not meet inclusion criteria,
203 59 failed pre-screening criteria and 89 declined study participation (**Figure 2**). Initially 46

204 participants were enrolled but 3 were excluded (operator error: 2; surgery cancellation: 1) for a
205 final cohort of 43 participants.

206 **Baseline characteristics:** Trial

207 participants had a median age of
208 68 (range: 60-86 years old), 46.5%
209 were female, and mean body mass
210 index (BMI) was 27.5 (± 6.0
211 kg/m^2). Preoperative RCRI was a
212 median of 1 (range: 1-2). Essential
213 hypertension (51.2%),
214 hyperlipidemia (39.5%) and solid

Figure 2



215 tumor (58.1%) were the most common pre-morbid conditions. Former or active smokers
216 comprised 51.2% of the cohort. Major abdominal surgeries (62.8%) comprised the majority of
217 the noncardiac surgical procedures. **Table 2** describes the baseline demographics of the study
218 population.


219 **Feasibility and participant smCPET acceptability:** The mean (SD) experimental session time
220 was 16.9 minutes (± 6.8). The mean (SD) modified Borg survey after experimental sessions was
221 5.35 (± 1.8), corresponding to moderate perceived exertion. On 24-hour post-experimental
222 session survey, a total of 43 (100%) of participants were reached. Mean (SD) patient satisfaction
223 [on a scale of 1 (worst) to 10 (best)] was 9.5 (± 1.5). The mean (SD) ease of performing smCPET
224 tasks was reported as 9.6 (± 0.7). Among this cohort, no major or minor complications associated
225 with study testing were reported by participants (0/43; 0%). Operational efficiency was achieved
226 within 10-15 experimental session among four study team members who trained on the device.

227 **Secondary measures:** Average self-reported peak METs was higher when compared to
228 smCPET equivalent (extrapolated peak METs) [7.6 (\pm 2.0) vs. 6.7 (\pm 1.8)]. DASI estimated peak
229 METs was higher when compared to smCPET equivalent (extrapolated peak METs) [8.8 (\pm 1.2)
230 vs. 6.7 (\pm 1.8)]. DASI-estimated peak VO₂ was higher than smCPET equivalent (extrapolated
231 peak VO₂) [30.9 (\pm 4.3) vs. 23.6 (\pm 6.5)]. **Figure 3** provides a comparison of values obtained from
232 smCPET compared to self-reported peak METs, DASI peak METs, and peak VO₂.

233 Discussion

234 The integration of
235 brief smCPET in a
236 high-volume PSE
237 clinic is feasible as
238 measured by
239 endpoints of session


Figure 3



240 time, patient satisfaction with smCPET task execution, perceived exertion, and session
241 scheduling. Secondly, operational efficiency of study team members was acceptable within 10-
242 15 experimental sessions. Lastly, we observed consistent underestimation of self-reported METs,
243 DASI peak METs, and DASI peak VO₂ when compared to smCPET equivalent values.
244 We found that smCPET set-up, calibration, patient instruction, and execution of the study trial
245 was time efficient. Mean session time was 16.9 minutes with rapid improvement over the study

246 time period as operators (n=4) became
247 facile with the study instrument (Figure
248 4). In fast paced, high-volume clinic
249 environments, this efficiency is
250 important, as patients are often seen
251 short notice for preoperative evaluation.
252 Given the short time requirement, we
253 were able to flexibly arrange smCPET

Figure 4



254 testing around other clinic appointments, facilitating successful study recruitment, and
255 decreasing time burden on participants. PSE clinic-performed smCPET was also associated with
256 a high level of patient satisfaction related to ease of task performance, and perceived exertion.
257 The tested device uses a stair-step for graded exercise, which was often familiar to participants.
258 The short duration of graded exercise, with automated verbal prompts to increase work rate by
259 the device, was not perceived by any participant as maximum effort by Borg survey. No
260 exercise-related major or minor complications were observed, and patients were consistently
261 encouraged to safely provide maximal effort within the graded exercise portion of smCPET.
262 Early termination of conventional CPET trials, due to participant fatigue or safety considerations,
263 has been reported to be approximately 11%, no participant in our feasibility cohort elected early
264 trial termination¹⁴. It is important to note that we selected for functionally independent
265 participants with self-reported >4.6 METs, as represented by the ability to climb two flights of
266 stairs, and expansion to less functional patients may result in higher failure rates. However,
267 smCPET has been successfully tested in high-risk and frail populations, suggesting that a wide
268 spectrum of preoperative populations could be tested using smCPET²⁶⁻²⁸.

269 In prior work, Wijeyesundera and colleagues¹⁴ observed that subjective clinician estimation had a
270 sensitivity of 19.2% in the identification of patients with low functional capacity (≤ 4 METs)¹⁴.
271 We observed that self-reported subjective METs and DASI estimated METs were, on average,
272 lower than their smCPET equivalent (extrapolated peak METs). In our analysis, 18.6% (N=8/43)
273 of participants self-reported their peak METs within 10% of smCPET extrapolated peak METs,
274 27.9% of participants underestimated (N=12/43) and 53% (23/43) overestimated their peak
275 METs by $>10\%$, respectively. smCPET identified that 18.6% (n=8) of our study cohort had ≤ 4.7
276 extrapolated peak METs, correlating very closely to a METs threshold associated with higher
277 perioperative cardiovascular morbidity and mortality. Furthermore, smCPET identified that
278 20.9% of our cohort had an age adjusted peak VO_2 of $<20\text{ml/kg/min}$, corresponding to poor
279 aerobic capacity, and 4.6% of our cohort achieved an extrapolated peak $\text{VO}_2 <15\text{ ml/kg/min}$.
280 It has been shown that conventional preoperative evaluation may not improve perioperative
281 outcomes²⁹. This may suggest a useful role for more precise risk stratification using brief
282 smCPET in preoperative testing. Despite supporting evidence, widespread adoption of CPET and
283 new generation smCPET devices has not been observed in preoperative testing. This is likely
284 multifactorial due to limited awareness of new generation smCPET devices, perceived overhead
285 cost, perceived time constraints, perceived operational complexity, and lack of clinical evidence
286 regarding preoperative clinic integration. However, further knowledge of smCPET predictive
287 validity and optimal system processes for selecting patients is required to identify its
288 preoperative testing indications and its role in preoperative evaluation.

289 **Study Limitations**

290 This study had several limitations related to generalizability to other populations. As an open-
291 label device clinical trial using a convenience sample of preoperative patients, we deliberately

292 excluded patients with high levels of comorbid conditions as quantified by RCRI. Although we
293 are not able to generalize to this population, our goal was to establish feasibility of brief
294 smCPET assessment within a presumed healthy but older perioperative cohort that would have
295 likely not been captured by extensive preoperative evaluation. Secondly, although published data
296 has validated smCPET predictive performance with perioperative cardiovascular morbidity and
297 mortality, our cohort is not yet powered for assessment of these outcomes. Finally, our
298 demonstration of no device-related adverse events is reassuring, but it should be cautiously
299 interpreted given the small sample size and possibility of rare exercise-induced adverse events.

300 **Conclusions**

301 In summary, we observed that smCPET was well accepted into the workflow of a high-volume
302 PSE clinic. All logistical, operational, and patient-centered feasibility endpoints were met.
303 Operator efficiency with the smCPET instrument was rapid and achieved relative parity at Day
304 30 or 10-15 sessions. This feasibility analysis has, 1) reinforced the structural integrity of our
305 active study protocol assessing relationships of smCPET findings with perioperative outcomes,
306 2) affirmed satisfactory patient-centered outcomes with the study procedures, and 3) provided
307 insight into functional capacity variation in a cohort of older, but otherwise functionally
308 independent, adult participants. Further studies should examine smCPET predictive validity and
309 optimal system processes for patient selection.

310 **Statements & Declarations**

311 **Funding Sources:** This study was partially supported by Shape Medical Systems, Inc.
312 (Minnesota, USA).

313 **Competing Interests:** The listed authors would like to disclose the following affiliations or
314 involvements: ZJC receives partial funding from Shape Medical Systems, Inc. (Minnesota, USA)

315 related to the present work. RBS reports owning stock in Johnson and Johnson unrelated to the
316 present work. RBS reports that Yale University has received funding from Merck for a study in
317 which he was involved, unrelated to the present work. PH reported receiving research support
318 grants from Edwards Lifesciences and consulting and/or royalty fees from Baudax Bio,
319 FireFoundry, Cardiage LLC, and Edwards Lifesciences.

320 **Author Contributions:** Study conception and design were performed by Zyad J. Carr, Paul
321 Heerdt, Robert B. Schonberger. The first draft of the manuscript was performed by Zyad J. Carr,
322 Jean Charchaflich, Jill Zafar, Andres Brenes-Bastos. Data collection was performed by Zyad J.
323 Carr, Jonah Freund, Judy Li, Daniel Agarkov. Statistical analysis was performed by Zyad J. Carr.
324 Further manuscript editing was performed by all co-authors. All authors read and approved the
325 final manuscript.

326 **Ethics Approval:** This study was performed in accordance with the principles of the Declaration
327 of Helsinki. Approval was granted by the Yale University (New Haven, Connecticut, USA)
328 Institutional Review Board (IRB#2000033885; ClinicalTrials.gov Registry. #NCT05743673.
329 Principal Investigator: Zyad J. Carr, M.D. Date of Registration: 5-12-2023).

330 **Consent to participate:** Informed consent was obtained from all individual participants included
331 in the study.

332 **Consent to publish:** All participant data is deidentified. Co-author Jonah Freund has given
333 express written consent for publication of his image in Figure 1.

334 **Data Availability:** A deidentified data set is available on request to the corresponding author
335 (Zyad J. Carr, zyad.carr@yale.edu).

336 **Acknowledgements:** We would like to acknowledge the work of Rayna Lewoc, DNP, APRN,
337 CRNA, Elizabeth Womack, Elizabeth Cozza, APRN, Gwendolyn Burkett, and the staff of the
338 Yale-New Haven Hospital Pre-Surgical Evaluation Clinic.
339

340 **Patient and Public Involvement:** Patient or the public were not involved in the design, or
341 conduct, or reporting, or dissemination plans of our research.

342

343

344 **References**

345

- 346 1. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on
347 perioperative cardiovascular evaluation and management of patients undergoing
348 noncardiac surgery: a report of the American College of Cardiology/American Heart
349 Association Task Force on practice guidelines. *J Am Coll Cardiol* 2014;64(22):e77-137.
350 doi: 10.1016/j.jacc.2014.07.944 [published Online First: 20140801]
- 351 2. Lurati Buse GAL, Puelacher C, Gualandro DM, et al. Association between self-reported
352 functional capacity and major adverse cardiac events in patients at elevated risk
353 undergoing noncardiac surgery: a prospective diagnostic cohort study. *British journal of*
354 *anaesthesia* 2021;126(1):102-10. doi: 10.1016/j.bja.2020.08.041 [published Online First:
355 20201017]
- 356 3. Reilly DF, McNeely MJ, Doerner D, et al. Self-reported exercise tolerance and the risk of
357 serious perioperative complications. *Arch Intern Med* 1999;159(18):2185-92. doi:
358 10.1001/archinte.159.18.2185
- 359 4. Biccard BM. Relationship between the inability to climb two flights of stairs and outcome
360 after major non-cardiac surgery: implications for the pre-operative assessment of
361 functional capacity. *Anaesthesia* 2005;60(6):588-93. doi: 10.1111/j.1365-
362 2044.2005.04181.x
- 363 5. Weinstein AS, Sigurdsson MI, Bader AM. Comparison of Preoperative Assessment of
364 Patient's Metabolic Equivalents (METs) Estimated from History versus Measured by
365 Exercise Cardiac Stress Testing. *Anesthesiology research and practice*
366 2018;2018:5912726. doi: 10.1155/2018/5912726 [published Online First: 20180903]
- 367 6. Nieves-Alonso JM, Méndez Hernández RM, Ramasco Rueda F, et al. Estimated metabolic
368 equivalents of task do not correlate with the maximal oxygen consumption of patients
369 undergoing lung resection surgery. *Rev Esp Anesthesiol Reanim (Engl Ed)*
370 2022;69(7):437-41. doi: 10.1016/j.redare.2021.01.006 [published Online First:
371 20220719]
- 372 7. Gray KD, Nobel TB, Hsu M, et al. Improved Preoperative Risk Assessment Tools Are Needed
373 to Guide Informed Decision Making before Esophagectomy. *Annals of surgery*
374 2023;277(1):116-20. doi: 10.1097/sla.0000000000004715
- 375 8. Glaab T, Taube C. Practical guide to cardiopulmonary exercise testing in adults. *Respiratory*
376 *research* 2022;23(1):9. doi: 10.1186/s12931-021-01895-6
- 377 9. Argillander TE, Heil TC, Melis RJF, et al. Preoperative physical performance as predictor of
378 postoperative outcomes in patients aged 65 and older scheduled for major abdominal
379 cancer surgery: A systematic review. *Eur J Surg Oncol* 2022;48(3):570-81. doi:
380 10.1016/j.ejso.2021.09.019 [published Online First: 20211001]
- 381 10. Loewen GM, Watson D, Kohman L, et al. Preoperative exercise Vo2 measurement for lung
382 resection candidates: results of Cancer and Leukemia Group B Protocol 9238. *J Thorac*
383 *Oncol* 2007;2(7):619-25. doi: 10.1097/JTO.0b013e318074bba7

- 384 11. Benzo R, Kelley GA, Recchi L, et al. Complications of lung resection and exercise capacity:
385 a meta-analysis. *Respiratory medicine* 2007;101(8):1790-7. doi:
386 10.1016/j.rmed.2007.02.012 [published Online First: 20070403]
- 387 12. Hartley RA, Pichel AC, Grant SW, et al. Preoperative cardiopulmonary exercise testing and
388 risk of early mortality following abdominal aortic aneurysm repair. *British Journal of*
389 *Surgery* 2012;99(11):1539-46. doi: 10.1002/bjs.8896
- 390 13. Older P, Hall A, Hader R. Cardiopulmonary exercise testing as a screening test for
391 perioperative management of major surgery in the elderly. *Chest* 1999;116(2):355-62.
392 doi: 10.1378/chest.116.2.355
- 393 14. Wijeyesundera DN, Pearse RM, Shulman MA, et al. Assessment of functional capacity before
394 major non-cardiac surgery: an international, prospective cohort study. *Lancet (London,*
395 *England)* 2018;391(10140):2631-40. doi: 10.1016/s0140-6736(18)31131-0
- 396 15. Ferguson M, Shulman M. Cardiopulmonary Exercise Testing and Other Tests of Functional
397 Capacity. *Curr Anesthesiol Rep* 2021:1-8. doi: 10.1007/s40140-021-00499-6 [published
398 Online First: 2021/11/30]
- 399 16. Baba R, Nagashima M, Goto M, et al. Oxygen uptake efficiency slope: a new index of
400 cardiorespiratory functional reserve derived from the relation between oxygen uptake and
401 minute ventilation during incremental exercise. *J Am Coll Cardiol* 1996;28(6):1567-72.
402 doi: 10.1016/s0735-1097(96)00412-3
- 403 17. Hollenberg M, Tager IB. Oxygen uptake efficiency slope: an index of exercise performance
404 and cardiopulmonary reserve requiring only submaximal exercise. *J Am Coll Cardiol*
405 2000;36(1):194-201. doi: 10.1016/s0735-1097(00)00691-4
- 406 18. Snowden CP, Prentis JM, Anderson HL, et al. Submaximal cardiopulmonary exercise testing
407 predicts complications and hospital length of stay in patients undergoing major elective
408 surgery. *Annals of surgery* 2010;251(3):535-41. doi: 10.1097/SLA.0b013e3181cf811d
- 409 19. Grocott MP, Browne JP, Van der Meulen J, et al. The Postoperative Morbidity Survey was
410 validated and used to describe morbidity after major surgery. *J Clin Epidemiol*
411 2007;60(9):919-28. doi: 10.1016/j.jclinepi.2006.12.003 [published Online First:
412 20070507]
- 413 20. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to
414 determine functional capacity (the Duke Activity Status Index). *Am J Cardiol*
415 1989;64(10):651-4. doi: 10.1016/0002-9149(89)90496-7
- 416 21. Ford MK, Beattie WS, Wijeyesundera DN. Systematic review: prediction of perioperative
417 cardiac complications and mortality by the revised cardiac risk index. *Annals of internal*
418 *medicine* 2010;152(1):26-35. doi: 10.7326/0003-4819-152-1-201001050-00007
- 419 22. Miller AD, Woods P.R., Olson T.P., Hulsebus M.L., O'Malley K.A., MacCarter D., Johnson
420 B.D. Validation of a Simplified, Portable Cardiopulmonary Gas Exchange
421 System for Submaximal Exercise Testing. *The Open Sports Medicine Journal* 2010;4:34-40. doi:
422 10.2174/1874387001004010034
- 423 23. Borg GA. Psychophysical bases of perceived exertion. *Medicine and science in sports and*
424 *exercise* 1982;14(5):377-81.
- 425 24. McAuley P, Myers J, Abella J, et al. Evaluation of a specific activity questionnaire to predict
426 mortality in men referred for exercise testing. *Am Heart J* 2006;151(4):890.e1-7. doi:
427 10.1016/j.ahj.2005.09.017
- 428 25. Bell EC, Cox NS, Goh N, et al. Oxygen therapy for interstitial lung disease: a systematic
429 review. *Eur Respir Rev* 2017;26(143) doi: 10.1183/16000617.0080-2016

- 430 10.1183/16000617.0080-2016. Print 2017 Jan. [published Online First: 2017/02/23]
431 26. Oakland HT, Joseph P, Elassal A, et al. Diagnostic utility of sub-maximum cardiopulmonary
432 exercise testing in the ambulatory setting for heart failure with preserved ejection
433 fraction. *Pulm Circ* 2020;10(4):2045894020972273. doi: 10.1177/2045894020972273
434 [published Online First: 20201125]
435 27. Bernstein EJ, Mandl LA, Gordon JK, et al. Submaximal heart and pulmonary evaluation: a
436 novel noninvasive test to identify pulmonary hypertension in patients with systemic
437 sclerosis. *Arthritis Care Res (Hoboken)* 2013;65(10):1713-8. doi: 10.1002/acr.22051
438 28. Woods PR, Frantz RP, Taylor BJ, et al. The usefulness of submaximal exercise gas exchange
439 to define pulmonary arterial hypertension. *J Heart Lung Transplant* 2011;30(10):1133-
440 42. doi: 10.1016/j.healun.2011.03.021 [published Online First: 20110531]
441 29. Beckerleg W, Kobewka D, Wijeyesundera DN, et al. Association of Preoperative Medical
442 Consultation With Reduction in Adverse Postoperative Outcomes and Use of Processes
443 of Care Among Residents of Ontario, Canada. *JAMA Intern Med* 2023;183(5):470-78.
444 doi: 10.1001/jamainternmed.2023.0325
445
446

447 Figure Legends

448
449 **Figure 1.** A visual representation of the smCPET device in the PSE Clinic. (Model: co-author
450 JF)

451
452 **Figure 2.** A Flow Diagram of Participant Enrollment.

453
454 **Figure 3.** Figure 3a reports differences between estimated peak METs between self-reported and
455 extrapolated peak METs derived from smCPET. Figure 3b reports differences between Duke
456 Activity Status Index estimated peak VO₂ and submaximal CPET extrapolated peak VO₂.
457

458 **Figure 4.** Operator Efficiency Measured by Session Time over the Study Time Period.
459

460 **Table 1.** Baseline Demographical Data of the Study Cohort (n=43).
461

462 **Supplementary Table 1.** Summary and Selected Measurements of Submaximal
463 Cardiopulmonary Exercise Testing.
464

465 **Supplementary Table 2.** Adapted Subjective METs Survey.
466
467
468

Table 1. Baseline Demographical Data of the Study Cohort (n=43)

Age, in years, median (range)	68	(60-86)
Gender		
Male	23	(53.5%)
Female	20	(46.5%)
Body Mass Index, in m/kg ² , mean (SD)	27.5	(±6.0)

Revised Cardiac Risk Index Score, median (Range)	1	(1-2)
Preoperative Comorbidities		
Essential Hypertension	22	(51.2%)
Hyperlipidemia	17	(39.5%)
Ventricular Dysrhythmia	1	(2.3%)
Congestive Heart Failure	1	(2.3%)
Myocardial Infarction	3	(7.0%)
Cerebrovascular Disease	1	(2.3%)
Chronic Obstructive Pulmonary Disease	3	(7.0%)
Asthma	4	(9.3%)
Obstructive Sleep Apnea	3	(7.0%)
History of Prior Lung Resection	1	(2.3%)
Diabetes Mellitus	7	(16.3%)
Thyroid Disorders	7	(16.3%)
Solid Tumor	25	(58.1%)
Anemia	1	(2.3%)
Social History		
Smoking		
Active	4	(9.3%)
Former	18	(41.9%)
Never	21	(48.8%)
Marijuana Use (active)	4	(9.3%)
Alcohol Use		
Active	24	(55.8%)
Former	16	(37.2%)
Never	3	(7.0%)
Cardiovascular Medication Use		
Beta-blocker	14	(32.6%)
Calcium channel antagonist	9	(20.9%)
ACE/ARB antagonist	16	(37.2%)
Diuretic	12	(27.9%)
Surgical Categories		
Abdominal Major	27	(62.8%)
Musculoskeletal Major	4	(9.3%)
Neurosurgical Major	2	(4.7%)
Thoracic Major	5	(11.6%)
Other Major	5	(11.6%)

469
470
471
472
473
474
475

Supplementary Table 1. Selected Measurements of Submaximal Cardiopulmonary Exercise Testing.

Variable	Description	Commentary
Summary of Shape II® metabolic analyzer used in study: The device uses breath by breath sampling during calibration and exercise challenge using a differential pressure pneumotach method for volume calibration and measurement, an infrared sensor for CO ₂ and a paramagnetic sensor for O ₂ measurements. Automated calibration using a calibration gas mixture (15.6% O ₂ /5% CO ₂) is performed at regular intervals. The Shape II calculations used for causes of exertional dyspnea differentiation are Artificial Intelligence (AI) based algorithms previously calibrated and validated against conventional cardiopulmonary exercise testing methods.		
HR (resting)	Resting heart rate	Measured during 1st stage prior to exercise.
HR (peak)	Peak heart rate achieved during exercise	Measured during 2nd stage during exercise.
% HR reserve utilized	Percentage of heart rate reserve utilized	Percentage of resting heart rate and the age-dependent predicted maximum heart rate
% HR max predicted attained	Percentage of predicted maximum achieved heart rate	Difference between maximum measured heart rate during exercise and age-dependent estimated maximum heart rate.
CRI	Chronotropic Recovery Index	A measure of heart rate recovery after exercise
RR rest	Respiratory rate at rest	Measured during 1st stage prior to exercise.
RR end exercise	End-exercise respiratory rate	Measured during 2nd stage during exercise.
End-tidal CO ₂ (rest)	End-tidal carbon dioxide, at rest	Influenced by cardiac output, pulmonary vascular resistance, and chronic hypoventilation syndromes
End-tidal CO ₂ (peak)	End-tidal carbon dioxide, peak exercise	Peak carbon dioxide during exercise
Resting SpO ₂	Resting pulse oximetry	Resting peripheral oxygenation
Peak SpO ₂	Peak exercise pulse oximetry	Peak exercise peripheral oxygenation
RER	Respiratory Exchange Ratio	Ratio between metabolic production of CO ₂ and uptake of O ₂
VE/VCO ₂ slope	Minute ventilation/CO ₂ production slope	Breathing efficiency slope reflects the efficiency of elimination of CO ₂
Δ EtCO ₂ (rest to end exercise)	Change in end-tidal carbon dioxide during exercise	A measure of cardiac output and pulmonary blood flow
Gxcap (peak)	Gas exchange-derived pulmonary vascular capacitance at peak exercise	Shown to correlate with cardiac output and inversely with pulmonary vascular resistance (PVR) and DLCO; in patients with PAH or PVH, Gxcap is reduced due to increased PVR.
OUES (linear slope)	Oxygen uptake efficiency slope, percentage of expected	Assesses how well oxygen is extracted from the inhaled air, distributed to the muscles by the cardiopulmonary system, and utilized by the muscles in energy metabolism; Particularly valuable in assessing exercise capacity and response to medications or rehabilitation
Peak Attained METs	Metabolic Equivalent	Metabolic equivalents attained during submaximal exercise.
Peak Extrapolated METs	Metabolic Equivalent	Peak estimated metabolic equivalents
O ₂ pulse	Amount of oxygen consumed per heartbeat	
Sub-maximal VO ₂ (peak attained)	Sub-maximal exercise oxygen uptake	Achieved peak maximal oxygen uptake during submaximal exercise.
Extrapolated maximum VO ₂	Predicted maximal exercise oxygen uptake	Calculated peak maximal oxygen uptake.

MVI score	Dimensionless; (cumulative sum score)	Combined cardiopulmonary index with threshold value of normal vs. impairment.
Cardiac disease silo score	Dimensionless; (cumulative sum score)	Parameters: VE/VCO ₂ slope, O ₂ pulse to VO ₂ slope, circulatory equivalents, HR recovery
Pulmonary Vascular Disease silo score	Dimensionless; (cumulative sum score)	Parameters: VE/VCO ₂ slope, peak Gx _{cap} , resting SpO ₂ , SpO ₂ desaturation
Chronic Obstructive Pulmonary Disease silo score	Dimensionless; (cumulative sum score)	Parameters: FEV1 % Predicted, breathing reserve, SpO ₂ desaturation, P mixed expired CO ₂ /P end-tidal CO ₂ ratio (V/Q ratio)
Restrictive Lung Disease silo score	Dimensionless; (cumulative sum score)	Parameters: FVC % Predicted, SpO ₂ desaturation, VT max / VT rest, RR/VCO ₂ slope (lung stiffness)
De-conditioning silo score	Dimensionless; (cumulative sum score)	Parameters: extrapolated peak VO ₂ , % ideal BMI, HR to VO ₂ linear regression slope, HR recovery 1 minute post exercise
V/Q plot	Dimensionless; (cumulative sum score); (Normal, Left ventricular dysfunction, Chronic Obstructive Pulmonary Disease, Transitional or Pulmonary Arterial Hypertension)	Assesses which physiological area may contribute to visualized impairments during submaximal exercise testing.
AwCap peak (VT pk x PECO ₂ peak)	airway capacitance; L x mmHg	Airway Capacitance
VT pk (peak attained VT)	Peak attained tidal volume in L/min	Value obtained during exercise.
VE peak (peak attained VE)	Peak attained minute ventilation in L/min	Value obtained during exercise.

Abbreviations: HR; heart rate; CRI; chronotropic Recovery Index; RR; respiratory rate (in breaths/min); CO₂; carbon dioxide; SpO₂; pulse oximetry; RER; respiratory Exchange Ratio; Gx_{cap}; pulmonary arterial capacitance; OUES; oxygen uptake efficiency slope; METs; metabolic equivalents; VO₂; oxygen consumption; MVI; multivariable index; VE; minute ventilation; VT; tidal volume; AwCap; airway capacitance.

476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492

Supplementary Table 2. Adapted Self-Reported Subjective Metabolic Equivalents Survey		
Question	Estimated Metabolic Equivalents	Accepted value
<i>Can you perform the following activities (yes/no)</i>		
Watching television, writing, desk work?	1-2	2
Walk slowly on level ground (1.7mph)	2-3	3
Climb two flights of stairs, without stopping to rest?	3-5	4
Walk at moderate pace on level ground (3mph/20 minute mile), ride a stationary bicycle at very light intensity or vacuum around the home?	3-5	4
Ride a stationary bicycle at moderate intensity?	5-6	6
Jogging, fast swimming, play soccer or tennis?	7-8	8
Run a 7.5 minute/mile, jump-rope 100 skips/minute, run up the stairs	10-13	10

493